cysteine and rrx-001

cysteine has been researched along with rrx-001 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Adams, CM; Fitch, WL; Luo, G; Marini, J; Musick, T; Oronsky, B; Scicinski, J; Taylor, M	1
Chen, Y; Deng, X; He, H; Jiang, W; Lin, B; Zhou, R	1

Other Studies

2 other study(ies) available for cysteine and rrx-001

Article	Year
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:9 Topics: Alkylation; Animals; Antineoplastic Agents; Azetidines; beta-Globins; Biotransformation; Chromatography, Liquid; Cysteine; Dogs; Erythrocytes; Haplorhini; Hemoglobins; Humans; Injections, Intravenous; Kidney; Male; Metabolic Clearance Rate; Nitro Compounds; Peptide Mapping; Protein Binding; Proteomics; Rats; Rats, Wistar; Sulfhydryl Compounds; Tandem Mass Spectrometry; Tissue Distribution	2012
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. Cellular & molecular immunology, 2021, Volume: 18, Issue:6 Topics: Animals; Azetidines; CARD Signaling Adaptor Proteins; Colitis; Cysteine; Dextran Sulfate; Encephalomyelitis, Autoimmune, Experimental; Inflammasomes; Inflammation; Lipopolysaccharides; Macrophages; Mice, Inbred C57BL; NIMA-Related Kinases; Nitro Compounds; NLR Family, Pyrin Domain-Containing 3 Protein; Protein Domains	2021

Article

Year

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.

Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:9

Topics: Alkylation; Animals; Antineoplastic Agents; Azetidines; beta-Globins; Biotransformation; Chromatography, Liquid; Cysteine; Dogs; Erythrocytes; Haplorhini; Hemoglobins; Humans; Injections, Intravenous; Kidney; Male; Metabolic Clearance Rate; Nitro Compounds; Peptide Mapping; Protein Binding; Proteomics; Rats; Rats, Wistar; Sulfhydryl Compounds; Tandem Mass Spectrometry; Tissue Distribution

2012

RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor.

Cellular & molecular immunology, 2021, Volume: 18, Issue:6

Topics: Animals; Azetidines; CARD Signaling Adaptor Proteins; Colitis; Cysteine; Dextran Sulfate; Encephalomyelitis, Autoimmune, Experimental; Inflammasomes; Inflammation; Lipopolysaccharides; Macrophages; Mice, Inbred C57BL; NIMA-Related Kinases; Nitro Compounds; NLR Family, Pyrin Domain-Containing 3 Protein; Protein Domains

2021